Disease course heterogeneity and OCT in multiple sclerosis

  title={Disease course heterogeneity and OCT in multiple sclerosis},
  author={L. J. Balk and Prejaas Tewarie and Joep Killestein and Chris H. Polman and B. M. J. Uitdehaag and Axel Petzold},
  journal={Multiple Sclerosis Journal},
  pages={1198 - 1206}
Background: The heterogeneity of the disease course in multiple sclerosis (MS) remains a challenge for patient management and clinical trials. Objective: The objective of this paper is to investigate the relationship between disease course heterogeneity and retinal layer thicknesses in MS. Methods: A total of 230 MS patients and 63 healthy control subjects were included. Spectral-domain OCT scanning of the peripapillary and macular regions was performed, followed by automated eight-layer… 

Figures and Tables from this paper

The association between retinal nerve fibre layer thickness and corpus callosum index in different clinical subtypes of multiple sclerosis
There is a correlation between the thickness of the RNFL and CCI values in MS patients with no history of optic neuritis, which suggests that OCT might be a suitable marker for neurodegeneration in MS clinical trials.
Spectral-Domain Optical Coherence Tomography Assessment in Treatment-Naïve Patients with Clinically Isolated Syndrome and Different Multiple Sclerosis Types: Findings and Relationship with the Disability Status
This study evaluates the peripapillary retinal nerve fiber layer (pRNFL) thickness and total macular volume (TMV) using spectral-domain optical coherence tomography in treatment naïve patients with
OCT Variability Prevents Their Use as Robust Biomarkers in Multiple Sclerosis
Although OCT is a valuable technology to improve MS patient assessment, differences between devices must be taken into account and it is necessary to create an international group that standardizes the measurement conditions and above all that provides reference bases for normal subjects.
Association of Retinal Layer Thickness With Cognition in Patients With Multiple Sclerosis
In patients with MS, at less advanced disease stages, RLT was especially associated with cognitive flexibility promoting OCT as a potential marker advocating further extensive neuropsychological examination.
Morphological Outer Retina Findings in Multiple Sclerosis Patients With or Without Optic Neuritis
In MS without history of ON or when ON is followed by a good BCVA recovery, the neurodegenerative process is limited to IR macular layers; in the presence of ON, with a poor BCVA Recovery, a morphological impairment of both IR and OR macular layer occurs.
Optical coherence tomography segmentation analysis in relapsing remitting versus progressive multiple sclerosis
Patients with PMS exhibit more atrophy of both the inner and outer retinal layers than RRMS, and the specific retinal layer predilection and its correlation with disability may reflect different pathophysiologic mechanisms and various stages of progression in MS.
Retinal ganglion cell analysis in multiple sclerosis and optic neuritis: a systematic review and meta-analysis
GCL thinning occurs in MS both with and without prior ON, and may be associated with visual function and EDSS score, which suggests that the GCL is a promising biomarker, which may be used to examine in vivo neurodegeneration in ON and MS.


Retinal Damage in Multiple Sclerosis Disease Subtypes Measured by High-Resolution Optical Coherence Tomography
Analysis of this large-scale cross-sectional dataset of MS patients studied with spectral-domain OCT confirmed and allows to generalize previous findings, carving out distinct patterns in different MS subtypes.
Active MS is associated with accelerated retinal ganglion cell/inner plexiform layer thinning
The findings suggest that retinal changes in MS reflect global CNS processes, and that OCT-derived GCIP thickness measures may have utility as an outcome measure for assessing neuroprotective agents, particularly in early, active MS.
Retinal Axonal Loss Begins Early in the Course of Multiple Sclerosis and Is Similar between Progressive Phenotypes
Retinal axonal loss is increasingly prominent in more advanced stages of disease – progressive MS>RRMS>CIS – with proportionally greater thinning in eyes previously affected by clinically evident optic neuritis.
An investigation of the retinal nerve fibre layer in progressive multiple sclerosis using optical coherence tomography.
There are significant global reductions in RNFLT and macular volume in the eyes of secondary progressive sclerosis patients not previously affected by ON, but not in primary progressive MS patients, compared with controls, which may indicate a difference in the extent of the pathological processes that cause axonal loss in the retina, and by inference the optic nerve.
Optical coherence tomography and disease subtype in multiple sclerosis
Retinal nerve fiber layer (RNFL) thickness is significantly decreased in multiple sclerosis (MS) optic neuritis (ON) eyes, unaffected fellow eyes of patients with MS ON, and MS eyes not affected by ON in the authors' cohort.
Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes
This first large study in untreated patients with multiple sclerosis with different disease subtypes shows that brain atrophy proceeds relentlessly throughout the course of MS, with a rate that seems largely independent of the MS subtype, when adjusting for baseline brain volume.
Degeneration of retinal layers in multiple sclerosis subtypes quantified by optical coherence tomography
The findings indicate a primary retinal pathology involving the inner nuclear layer in primary progressive MS, and suggest possible subclinical episodes of optic neuritis or retrograde trans-synaptic degeneration of retinal ganglion cells and their axons.
Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype.
The rate of development of brain atrophy is largely independent of the course of the disease and other clinical characteristics, thereby stressing the need for early neuroprotective treatment in MS.